Key Points
- Insider sale: Isabel Kalofonos sold 2,500 shares on Jan. 5 at an average of $55 for proceeds of $137,500, leaving her with 834 shares — a ~75% reduction in her position.
- Market snapshot: CRNX was trading up about 16.1% and opened at $53.34; the company has a market cap of roughly $5.06 billion and a 12‑month range of $24.10–$57.99.
- Fundamentals and sentiment: Crinetics missed quarterly EPS expectations (‑$1.38 vs. ‑$1.27) with weak revenue, while analysts hold a consensus "Moderate Buy" rating and an average price target of $77.55 (11 Buys, 2 Holds, 1 Sell).
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Isabel Kalofonos sold 2,500 shares of the business's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $55.00, for a total transaction of $137,500.00. Following the sale, the insider directly owned 834 shares in the company, valued at approximately $45,870. This represents a 74.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Crinetics Pharmaceuticals Trading Up 16.1%
CRNX stock opened at $53.34 on Thursday. The company has a market cap of $5.06 billion, a price-to-earnings ratio of -11.77 and a beta of 0.20. The firm has a 50 day moving average of $45.76 and a 200-day moving average of $38.26. Crinetics Pharmaceuticals, Inc. has a 12-month low of $24.10 and a 12-month high of $57.99.
Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.11). The company had revenue of $0.14 million during the quarter, compared to analysts' expectations of $0.39 million. During the same period in the previous year, the company posted ($0.96) earnings per share. Sell-side analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current fiscal year.
Institutional Trading of Crinetics Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in CRNX. Farther Finance Advisors LLC grew its position in Crinetics Pharmaceuticals by 523.7% during the third quarter. Farther Finance Advisors LLC now owns 842 shares of the company's stock valued at $35,000 after acquiring an additional 707 shares during the period. Headlands Technologies LLC purchased a new position in Crinetics Pharmaceuticals in the second quarter valued at approximately $30,000. Covestor Ltd lifted its position in Crinetics Pharmaceuticals by 23,983.3% during the third quarter. Covestor Ltd now owns 1,445 shares of the company's stock valued at $60,000 after buying an additional 1,439 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Crinetics Pharmaceuticals during the second quarter worth approximately $45,000. Finally, Abich Financial Wealth Management LLC purchased a new position in shares of Crinetics Pharmaceuticals in the 3rd quarter valued at $68,000. 98.51% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research analysts recently issued reports on the company. Citizens Jmp cut their price objective on Crinetics Pharmaceuticals from $108.00 to $105.00 and set a "market outperform" rating for the company in a research report on Thursday. JPMorgan Chase & Co. decreased their price objective on Crinetics Pharmaceuticals from $53.00 to $52.00 and set an "overweight" rating on the stock in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a research note on Wednesday, October 8th. JMP Securities boosted their price objective on shares of Crinetics Pharmaceuticals from $86.00 to $143.00 and gave the company a "market outperform" rating in a research report on Friday, September 26th. Finally, Leerink Partners boosted their price target on Crinetics Pharmaceuticals from $80.00 to $88.00 and gave the company an "outperform" rating in a report on Monday, September 29th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Crinetics Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $77.55.
Read Our Latest Stock Report on CRNX
Crinetics Pharmaceuticals Company Profile
(
Get Free Report)
Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.
The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
